According to the results of both DAPA-HF [13] and EMPEROR-R [14], the FDA have approved both dapagliflozin and empagliflozin to reduce the risk of CV death or hospitalization for HF in adults with HF and reduced ejection fraction regardless of whether they have diabetes
Key outcomes: Mean weight loss: 14.9% (vs 2.4% placebo) 86.4% of participants achieved 5% loss (vs 31.5% placebo) 50.5% achieved 15% loss (vs 4.9% placebo) SELECT (Lincoff et al., NEJM 2023) added the cardiovascular signature: in 17,604 non-diabetic adults with prior CV history, semaglutide 2.4 mg reduced MACE (CV death, MI, stroke) by 20% over 3 years
Lost wages and diminished earning capacity compensate for income disruptions caused by Ozempic injuries during active treatment and extending into future years if permanent disabilities impair work performance
Genome-wide association studies suggest that glutamatergic neurotransmission and NMDA receptor-mediated synaptic plasticity are important for body weight homeostasis 1
For type 2 diabetes, treatment duration depends on ongoing glycaemic control and tolerability, often requiring long-term therapy
Put simply, Temu shopping reviews are customer feedback and ratings shared by buyers on the newly-popular Temu platform
